Adenosine Contrast Correlations in Evaluating Revascularization: The (ACCELERATION) Study.

IF 6.1 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Rajesh V Swaminathan, Guillaume Marquis-Gravel, Laurie-Anne Boivin-Proulx, Daniel K Benjamin, Aruna Rikhi, Ganesh Raveendran, Jeff W Chambers, Arnold H Seto, Jayant Bagai, Roseann White, Jorge Antonio Gutierrez, Thomas J Povsic, Sunil V Rao, Mitchell W Krucoff
{"title":"Adenosine Contrast Correlations in Evaluating Revascularization: The (ACCELERATION) Study.","authors":"Rajesh V Swaminathan, Guillaume Marquis-Gravel, Laurie-Anne Boivin-Proulx, Daniel K Benjamin, Aruna Rikhi, Ganesh Raveendran, Jeff W Chambers, Arnold H Seto, Jayant Bagai, Roseann White, Jorge Antonio Gutierrez, Thomas J Povsic, Sunil V Rao, Mitchell W Krucoff","doi":"10.1161/CIRCINTERVENTIONS.125.015240","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Injection of contrast media for rapid measurement of contrast fractional flow reserve (cFFR) obviates the side effects and time requirements of adenosine fractional flow reserve (aFFR) and improves diagnostic performance relative to nonhyperemic pressure ratios. However, studies of cFFR have had variable delivery of contrast. We evaluated the diagnostic performance of cFFR using an automated contrast injector with a standardized volume and rate of delivery of contrast to the reference standard aFFR.</p><p><strong>Methods: </strong>The ACCELERATION study (Adenosine Contrast Correlations in Evaluating Revascularization) is an investigator-initiated, multicenter, prospective, single-arm trial conducted in 5 sites across the United States. cFFR and aFFR were measured in patients with stable coronary artery disease and intermediate stenosis (40% to 70%) using the ACIST CVi automated contrast injector (iopamidol; left coronary: rate of 4 mL/s, volume of 10 cm<sup>3</sup> and right coronary: rate of 3 mL/s, volume of 6 cm<sup>3</sup>) and RXi/Navvus FFR microcatheter. The diagnostic performance of cFFR was assessed using a 0.83 cutoff value based on published literature. Optimal cFFR cutoffs were also determined and illustrated using Bland-Altman analysis.</p><p><strong>Results: </strong>A total of 192 lesions from 178 patients were included in the per-protocol analysis (69 with an aFFR ≤0.80 and 109 with an aFFR >0.80). Using a cFFR cutoff value of ≤0.83, the accuracy, sensitivity, and specificity of cFFR were 0.89 (95% CI, 0.83-0.93), 0.70 (95% CI, 0.58-0.81), and 0.99 (95% CI, 0.95-1.00), respectively. The mean difference between cFFR and aFFR was 0.05 (-0.04 to 0.13). A cFFR threshold of ≤0.85 had the highest accuracy in predicting aFFR ≤0.80 with accuracy, sensitivity, and specificity equaling 0.90 (95% CI, 0.84-0.94), 0.87 (95% CI, 0.77-0.94), and 0.91 (95% CI, 0.84-0.95), respectively.</p><p><strong>Conclusions: </strong>cFFR utilizing standardized parameters for contrast delivery leads to clinically acceptable levels of diagnostic performance compared with traditional aFFR to identify physiologically significant intermediate lesions. Future data evaluating the impact on clinical outcomes of cFFR-guided percutaneous coronary intervention are warranted.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT03557385.</p>","PeriodicalId":10330,"journal":{"name":"Circulation: Cardiovascular Interventions","volume":" ","pages":"e015240"},"PeriodicalIF":6.1000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation: Cardiovascular Interventions","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/CIRCINTERVENTIONS.125.015240","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Injection of contrast media for rapid measurement of contrast fractional flow reserve (cFFR) obviates the side effects and time requirements of adenosine fractional flow reserve (aFFR) and improves diagnostic performance relative to nonhyperemic pressure ratios. However, studies of cFFR have had variable delivery of contrast. We evaluated the diagnostic performance of cFFR using an automated contrast injector with a standardized volume and rate of delivery of contrast to the reference standard aFFR.

Methods: The ACCELERATION study (Adenosine Contrast Correlations in Evaluating Revascularization) is an investigator-initiated, multicenter, prospective, single-arm trial conducted in 5 sites across the United States. cFFR and aFFR were measured in patients with stable coronary artery disease and intermediate stenosis (40% to 70%) using the ACIST CVi automated contrast injector (iopamidol; left coronary: rate of 4 mL/s, volume of 10 cm3 and right coronary: rate of 3 mL/s, volume of 6 cm3) and RXi/Navvus FFR microcatheter. The diagnostic performance of cFFR was assessed using a 0.83 cutoff value based on published literature. Optimal cFFR cutoffs were also determined and illustrated using Bland-Altman analysis.

Results: A total of 192 lesions from 178 patients were included in the per-protocol analysis (69 with an aFFR ≤0.80 and 109 with an aFFR >0.80). Using a cFFR cutoff value of ≤0.83, the accuracy, sensitivity, and specificity of cFFR were 0.89 (95% CI, 0.83-0.93), 0.70 (95% CI, 0.58-0.81), and 0.99 (95% CI, 0.95-1.00), respectively. The mean difference between cFFR and aFFR was 0.05 (-0.04 to 0.13). A cFFR threshold of ≤0.85 had the highest accuracy in predicting aFFR ≤0.80 with accuracy, sensitivity, and specificity equaling 0.90 (95% CI, 0.84-0.94), 0.87 (95% CI, 0.77-0.94), and 0.91 (95% CI, 0.84-0.95), respectively.

Conclusions: cFFR utilizing standardized parameters for contrast delivery leads to clinically acceptable levels of diagnostic performance compared with traditional aFFR to identify physiologically significant intermediate lesions. Future data evaluating the impact on clinical outcomes of cFFR-guided percutaneous coronary intervention are warranted.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03557385.

评价血运重建的腺苷对比相关性:加速研究。
背景:注射造影剂快速测量对比分数血流储备(cFFR)可消除腺苷分数血流储备(aFFR)的副作用和时间要求,并提高相对于非充血压比的诊断性能。然而,cFFR的研究有不同的造影剂输送。我们使用自动造影剂注射器评估cFFR的诊断性能,该注射器具有标准化的体积和对照标准aFFR的造影剂输送速率。方法:加速研究(评估血运重建的腺苷对比相关性)是一项研究者发起的、多中心、前瞻性、单臂试验,在美国5个地点进行。使用ACIST CVi自动造影剂(iopamidol;左冠状动脉:流速4 mL/s,容积10 cm3,右冠状动脉:流速3 mL/s,容积6 cm3), RXi/Navvus FFR微导管。根据已发表的文献,使用0.83的截止值评估cFFR的诊断性能。还确定了最佳cFFR截止点,并使用Bland-Altman分析说明了这一点。结果:178例患者共192个病变被纳入按方案分析(69例aFFR≤0.80,109例aFFR为0.80)。采用cFFR截断值≤0.83时,cFFR的准确性、敏感性和特异性分别为0.89 (95% CI, 0.83-0.93)、0.70 (95% CI, 0.58-0.81)和0.99 (95% CI, 0.95-1.00)。cFFR与aFFR的平均差异为0.05(-0.04 ~ 0.13)。当cFFR阈值≤0.85时,预测aFFR≤0.80的准确率最高,准确度、灵敏度和特异性分别为0.90 (95% CI, 0.84-0.94)、0.87 (95% CI, 0.77-0.94)和0.91 (95% CI, 0.84-0.95)。结论:与传统aFFR相比,使用标准化参数进行造影剂输送的cFFR在识别生理上显著的中间病变方面达到了临床可接受的诊断水平。未来评估cffr引导下经皮冠状动脉介入治疗对临床结果影响的数据是有根据的。注册:网址:https://www.clinicaltrials.gov;唯一标识符:NCT03557385。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Circulation: Cardiovascular Interventions
Circulation: Cardiovascular Interventions CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
10.30
自引率
1.80%
发文量
221
审稿时长
6-12 weeks
期刊介绍: Circulation: Cardiovascular Interventions, an American Heart Association journal, focuses on interventional techniques pertaining to coronary artery disease, structural heart disease, and vascular disease, with priority placed on original research and on randomized trials and large registry studies. In addition, pharmacological, diagnostic, and pathophysiological aspects of interventional cardiology are given special attention in this online-only journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信